Chronic Lymphocytic Leukemia
April 2017 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Chronic Lymphocytic Leukemia abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Chronic Lymphocytic Leukemia. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Chronic Lymphocytic Leukemia. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Chronic Lymphocytic Leukemia every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Magic pills: new oral drugs to treat chronic lymphocytic leukemia.
Authors:Vitale C, Griggio V, Todaro M, Salvetti C, Boccadoro M, Coscia M
Institution:a Division of Hematology , University of Torino, AOU Citta della Salute e della Scienza di Torino , Torino , Italy. Torino , Torino , Italy. Scienza di Torino , Torino , Italy. Torino , Torino , Italy. Scienza di Torino , Torino , Italy. Torino , Torino , Italy. Scienza di Torino , Torino , Italy. Torino , Torino , Italy. Scienza di Torino , Torino , Italy. Torino , Torino , Italy. Scienza di Torino , Torino , Italy. Torino , Torino , Italy.
Journal:Expert Opin Pharmacother. 2017 Mar;18(4):411-425. doi: 10.1080/14656566.2017.1293655. Epub 2017 Feb 22.

2:Synergistic induction of apoptosis in B-cell chronic lymphocytic leukemia cells after treatment with all-trans retinoic acid in combination with interleukin-21 and rituximab.
Authors:Abbaszadeh-Goudarzi K, Shokri F, Hosseini M, Jadidi-Niaragh F, Ghalamfarsa G, Saboor-Yaraghi AA
Institution:Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. Sciences, Tehran, Iran. University of Medical Sciences, Tehran, Iran. Sciences, Tehran, Iran. Yasuj, Iran. Sciences; Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
Journal:J Cancer Res Ther. 2016 Oct-Dec;12(4):1278-1283. doi: 10.4103/0973-1482.184522.

3:Receptor tyrosine kinase-like orphan receptor 1 (ROR-1): An emerging target for diagnosis and therapy of chronic lymphocytic leukemia.
Authors:Aghebati-Maleki L, Shabani M, Baradaran B, Motallebnezhad M, Majidi J, Yousefi M
Institution:Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. Medical Sciences, Tehran, Iran. Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: jmajidiz@yahoo.com. Iran; Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: yousefime@tbzmed.ac.ir.
Journal:Biomed Pharmacother. 2017 Apr;88:814-822. doi: 10.1016/j.biopha.2017.01.070. Epub 2017 Feb 1.

4:Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia.
Authors:Ishizawa K, Fukuhara N, Nakaseko C, Chiba S, Ogura M, Okamoto A, Sunaga Y, Tobinai K
Institution:Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi kishizaw@med.id.yamagata-u.ac.jp. Medicine, Sendai, Miyagi. Ibaraki. Aichi.
Journal:Jpn J Clin Oncol. 2017 Jan;47(1):54-60. doi: 10.1093/jjco/hyw146. Epub 2016 Oct 7.

5:Front-line treatment of CLL in the era of novel agents.
Authors:Robak T, Stilgenbauer S, Tedeschi A
Institution:Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93-510 Lodz, ul. Ciolkowskiego 2, Poland. Electronic address: robaktad@csk.umed.lodz.pl. Ulm 89081, Germany. Electronic address: Stephan.Stilgenbauer@uniklinik-ulm.de. Ospedale Maggiore 3, 20162 Milano, Italy. Electronic address: alessandra.tedeschi@ospedaleniguarda.it.
Journal:Cancer Treat Rev. 2017 Feb;53:70-78. doi: 10.1016/j.ctrv.2016.12.007. Epub 2016 Dec 30.

6:Targeted Therapy of CLL.
Authors:Al-Sawaf O, Fischer K, Eichhorst B, Hallek M
Institution:Department I of Internal Medicine, German CLL Study Group, Center for Integrated Oncology Cologne-Bonn, University Hospital of Cologne, Cologne, Germany.
Journal:Oncol Res Treat. 2016;39(12):768-778. Epub 2016 Nov 15.

7:The safety profile of monoclonal antibodies for chronic lymphocytic leukemia.
Authors:Korycka-Wolowiec A, Wolowiec D, Robak T
Institution:a Department of Hematology Medical , University of Lodz , Lodz , Poland.
Journal:Expert Opin Drug Saf. 2017 Feb;16(2):185-201. doi: 10.1080/14740338.2017.1264387. Epub 2016 Dec 4.

8:Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.
Authors:Al-Sawaf O, Fischer K, Herling CD, Ritgen M, Bottcher S, Bahlo J, Elter T, Stilgenbauer S, Eichhorst BF, Busch R, Elberskirch U, Abenhardt W, Kneba M, Hallek M, Wendtner CM
Institution:Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study group, University of Cologne, Cologne, Germany. German CLL Study group, University of Cologne, Cologne, Germany. German CLL Study group, University of Cologne, Cologne, Germany. Germany. Germany. German CLL Study group, University of Cologne, Cologne, Germany. German CLL Study group, University of Cologne, Cologne, Germany. German CLL Study group, University of Cologne, Cologne, Germany. Germany. German CLL Study group, University of Cologne, Cologne, Germany. Germany. German CLL Study group, University of Cologne, Cologne, Germany. German CLL Study group, University of Cologne, Cologne, Germany. Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany.
Journal:Eur J Haematol. 2017 Mar;98(3):254-262. doi: 10.1111/ejh.12825. Epub 2016 Dec 1.

9:Individual differences in physical symptom burden and psychological responses in individuals with chronic lymphocytic leukemia.
Authors:Morrison EJ, Flynn JM, Jones J, Byrd JC, Andersen BL
Institution:Department of Psychiatry and Psychology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. morrison.eleshia@mayo.edu. 10th Avenue, Columbus, OH, 43210, USA. 10th Avenue, Columbus, OH, 43210, USA. OH, 43210, USA.
Journal:Ann Hematol. 2016 Dec;95(12):1989-1997. Epub 2016 Aug 19.

10:Secondary immunodeficiency in lymphoproliferative malignancies.
Authors:Friman V, Winqvist O, Blimark C, Langerbeins P, Chapel H, Dhalla F
Institution:Department of Infectious Diseases, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. Stockholm, Sweden. Hospital, Gothenburg, Sweden. Cologne, Cologne, Germany.
Journal:Hematol Oncol. 2016 Sep;34(3):121-32. doi: 10.1002/hon.2323. Epub 2016 Jul 12.

11:Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.
Authors:Liang L, Zhao M, Zhu YC, Hu X, Yang LP, Liu H
Institution:Department of Pharmacy, Assessment of Clinical Drugs Risk and Individual Application Key Laboratory, Beijing Hospital, Beijing, 100730, China. Application Key Laboratory, Beijing Hospital, Beijing, 100730, China. Application Key Laboratory, Beijing Hospital, Beijing, 100730, China. Application Key Laboratory, Beijing Hospital, Beijing, 100730, China. Application Key Laboratory, Beijing Hospital, Beijing, 100730, China. liuhui8140@126.com.
Journal:Ann Hematol. 2016 Sep;95(9):1473-82. doi: 10.1007/s00277-016-2719-6. Epub 2016 Jun 21.

12:Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Authors:Barrientos JC
Institution:CLL Research & Treatment Program, Division of Hematology/Oncology, Department of Medicine, Hofstra Northwell School of Medicine, Hofstra University, 410 Lakeville Road, Suite 212, Lake Success, NY 11042, USA.
Journal:Future Oncol. 2016 Sep;12(18):2077-94. doi: 10.2217/fon-2016-0003. Epub 2016 Jun 21.

13:Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.
Authors:Maurer C, Pflug N, Bahlo J, Kluth S, Rhein C, Cramer P, Gross-Ophoff C, Langerbeins P, Fink AM, Eichhorst B, Kreuzer KA, Fischer N, Tausch E, Stilgenbauer S, Bottcher S, Dohner H, Kneba M, Dreyling M, Binder M, Hallek M, Wendtner CM, Bergmann M, Fischer K
Institution:Department I of Internal Medicine, Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany. University of Cologne, Cologne, Germany. University of Cologne, Cologne, Germany. University of Cologne, Cologne, Germany. University of Cologne, Cologne, Germany. University of Cologne, Cologne, Germany. University of Cologne, Cologne, Germany. University of Cologne, Cologne, Germany. University of Cologne, Cologne, Germany. University of Cologne, Cologne, Germany. University of Cologne, Cologne, Germany. Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany. Kiel, Kiel, Germany. Kiel, Kiel, Germany. Germany. Tumorzentrum/UVVH, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Cluster of Excellence on "Cellular Stress Responses in Aging" (CECAD), University of Cologne, Cologne, Germany. University of Cologne, Cologne, Germany. Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany. Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany. University of Cologne, Cologne, Germany.
Journal:Eur J Haematol. 2016 Sep;97(3):253-60. doi: 10.1111/ejh.12714. Epub 2016 Feb 9.

For a FREE PREVIEW of the Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Chronic Lymphocytic Leukemia...
at a Special 20% Discount


Medifocus Guidebook on Chronic Lymphocytic Leukemia

Updated: January 22, 2017
181 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Chronic Lymphocytic Leukemia is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

CL42410230

Coupon Expires: May 29, 2017



What Our Customers Are Saying...

"I was recently diagnosed with CLL and searched all over the Web for information. I found the MediFocus Guidebook on Chronic Lymphocytic Leukemia to be a very useful resource. The information about chemotherapy was most important to me as well as recent studies concerning general treatments for this condition. The most valuable information was contained in the extensive references listed which were easy to access with a simple 'mouse' click. You are welcome to use my name as a reference."
G.C.
Coedpoeth, United Kingdom



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.